Evidence map›Paper›PMID 41405787›Full record

ReviewInsights into imaging2025

From Radiomics to Radiogenomics: Decoding Renal Cell Carcinoma Biology for Precision Medicine-a narrative review.

Zihan He, Liping Huang

Abstract readReview
In one paragraph

Review in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zihan HeDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Liping HuangDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. lipinghuang08@163.com.ORCID http://orcid.org/0009-0006-3851-3604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma is a prevalent malignancy affecting the urinary system and poses significant challenges in precision diagnosis and treatment. Although medical imaging technologies have been widely applied in renal cell carcinoma screening, traditional imaging diagnostics have limitations due to their high degree of subjectivity, relying primarily on the doctor's experiential judgment. The advent of radiomics presents a groundbreaking method for tackling this issue-by extracting high-throughput, deep-level information from conventional medical images to achieve a quantitative assessment of tumor characteristics. Furthermore, the fusion of radiomics and genomics has led to radiogenomics, which combines imaging features with molecular data, enabling the non-invasive evaluation of tumor biological behavior, molecular heterogeneity, and microenvironmental features, thereby providing a more detailed, accurate, and personalized assessment. In this review, we summarize the role radiomics and radiogenomics play in the diagnosis, prediction, and adjuvant treatment of renal cell carcinoma. Radiomics has demonstrated potential in classifying renal cell carcinoma subtypes, predicting patient prognosis, and forecasting disease progression. Radiogenomics further links imaging features to gene mutations and the tumor microenvironment, enabling non-invasive assessment of renal cell carcinoma biology and providing new approaches to diagnosis and treatment. CRITICAL RELEVANCE STATEMENT: By reviewing existing research, we summarize how radiomics and radiogenomics address key clinical challenges in the diagnosis and treatment of renal cell carcinoma, providing non-invasive solutions to overcome tumor heterogeneity and guide precision oncology. KEY POINTS: Renal cell carcinoma lacks reliable non-invasive biomarkers for precision diagnosis and characterization. Radiogenomics bridges imaging and molecular biology for precise predictions. Radiogenomics lacks full multi-omics integration despite data growth.

Indexed as

Artificial intelligencePrecision medicineRadiogenomicsRadiomicsRenal cell carcinoma

Identifiers

PMID41405787
PMCPMC12711618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.